Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Minneapolis, Minnesota 55455


Purpose:

The purpose of this study is to determine whether thymic shielding during total body irradiation can be given and whether it will reduce the risk of infections in Fanconi Anemia patients undergoing alternate donor (not a matched sibling) stem cell transplants.


Study summary:

All subjects will be given the same treatment regimen of total body irradiation (TBI), Fludarabine, Cyclophosphamide, and anti-thymocyte globulin (ATG), followed by an alternate donor stem cell transplant. Since this treatment regimen has been given before, without thymic shielding, we will compare the outcomes of these patients with the historical data from subjects who did not receive thymic shielding.


Criteria:

Inclusion Criteria: - Patients must be less than (<) 18 years of age with a diagnosis of Fanconi anemia. - Patients must have an HLA-A, B, DRB1 identical unrelated donor or less than or equal to (≤)1 antigen mismatched related (non-HLA-matched sibling) or <1 antigen mismatched unrelated UCB donor. Patients and donors will be typed for HLA-A and B using serological or molecular techniques and for DRB1 using high resolution molecular typing. - Patients with FA must have aplastic anemia (AA), myelodysplastic syndrome without excess blasts, or high risk genotype as defined below. - Aplastic anemia is defined as having at least one of the following when not receiving growth factors or transfusions - Platelet count <20 x 10^9/L - ANC <5 x 10^8/L - Hgb <8 g/dL - Myelodysplastic syndrome with multilineage dysplasia with or without chromosomal anomalies - High risk genotype (e.g. IVS-4 or exon 14 FANCC mutations, or BRCA1 or 2 mutations) - Adequate major organ function including - Cardiac: ejection fraction greater than (>)45% - Hepatic: bilirubin, AST/ALT, ALP <2 x normal - Karnofsky performance status >70% or Lansky performance status >50% - Women of child-bearing age must be using adequate birth control and have a negative pregnancy test Exclusion Criteria: - Available HLA-genotypically identical related donor - History of gram negative sepsis or systemic fungal infection (proven or suspected based on radiographic studies) - Refractory anemia with excess blasts, or leukemia - Active central nervous system (CNS) leukemia at time of hematopoietic cell transplant (HCT) - History of squamous cell carcinoma of the head/neck/cervix within 2 years of HCT - Pregnant or lactating female - Prior radiation therapy preventing use of total body irradiation (TBI) 450 centigray (cGy)


NCT ID:

NCT00167206


Primary Contact:

Principal Investigator
Margaret MacMillan, MD
Masonic Cancer Center, University of Minnesota


Backup Contact:

N/A


Location Contact:

Minneapolis, Minnesota 55455
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.